drugset / Trial / NCT06683508

A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight

NCT06683508

Phase 2 Completed 288 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment

Summary

The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to evaluate the effects of LY3549492 in adults with obesity or overweight. Participation in the study will last about one year.

Timeline

Start
2024-11-13
Primary completion
2026-01-07
Completion
2026-05-04

Drugs

EvaluationDrugModalityDoseRoute
Subject LY3549492 Unknown Oral

Indications